NEW RESEARCH ORGANIZATION STRUCTURE
R&D Meeting - December 7, 2021
CAUTIONARY STATEMENT | |
2 | |
REGARDING FORWARD-LOOKING INFORMATION | |
In this material, statements made with respect to current plans, estimates, strategies and beliefs and other statements that are not historical facts are forward-looking statements about the future performance of Astellas Pharma. These statements are based on management's current assumptions and beliefs in light of the information currently available to it and involve known and unknown risks and uncertainties. A number of factors could cause actual results to differ materially from those discussed in the forward-looking statements. Such factors include, but are not limited to: (i) changes in general economic conditions and in laws and regulations, relating to pharmaceutical markets, (ii) currency exchange rate fluctuations, (iii) delays in new product launches, (iv) the inability of Astellas to market existing and new products effectively,
- the inability of Astellas to continue to effectively research and develop products accepted by customers in highly competitive markets, and (vi) infringements of Astellas' intellectual property rights by third parties.
Information about pharmaceutical products (including products currently in development) which is included in this material is not intended to constitute an advertisement or medical advice.
AGENDA | 3 |
Introduction
1 Naoki Okamura
Representative Director, Executive Vice President, CStO and CFO, CBO
New Research Organization
2 Yoshitsugu Shitaka, Ph.D. Corporate Executive, CScO
CStO: Chief Strategy Officer, CFO: Chief Financial Officer, CBO: Chief Business Officer, CScO: Chief Scientific Officer
INTRODUCTION
Naoki Okamura
Representative Director, Executive Vice President
Chief Strategy Officer (CStO) and Chief Financial Officer (CFO) Chief Business Officer (CBO)
VALUE CREATION THROUGH RESEARCH ACTIVITIES 5
Continuously create unique programs by driving Focus Area approach toward sustainable growth over the long term
Research based on
Focus Area approach
*
Beyond FY30
* Adapted from "What Is Value in Health Care?" Porter, M.E. (2010). New England Journal of Medicine
This is an excerpt of the original content. To continue reading it, access the original document here.
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
Astellas Pharma Inc. published this content on 07 December 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 07 December 2021 03:11:03 UTC.